Please login to the form below

Not currently logged in
Email:
Password:

Embeda

This page shows the latest Embeda news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs Pfizer and Teva abuse-resistant painkillers

FDA panel backs Pfizer and Teva abuse-resistant painkillers

Pfizer already sells an abuse-resistant formulation of morphine called Embeda, which uses the same naltrexone technology and was awarded an oral and intranasal abuse claim in 2014, but without an

Latest news

  • Opioid analgesics

    Pfizer's Embeda combines morphine and naltrexone in a single extended-release capsule. ... This, combined with the post-marketing data, suggest that Embeda is providing much-needed pain relief in this patient population without exposure to the risk of

  • Pfizer to buy King for $3.6bn

    sprains and bruises; and Embeda (morphine sulphate/ naltrexone hydrochloride), which was approved in August of this year as the first long-acting opioid that is designed to reduce drug liking and

  • King's profits hit by generic competition

    Its pain drug Embeda (morphine sulfate and naltrexone hydrochloride) is showing continued growth since it launched in September 2010 and reaped $15m during the second quarter.

  • Clouded vision

    Teva Pharmaceuticals). Emergency contraception . US. Morphine sulfate naltrexone hydrochloride. EMBEDA (King Pharmaceuticals).

  • King Pharma announce unexpected profit

    The company is currently focusing on gaining regulatory approvals for its trio of opioid products for treating late-stage pain: Remoxy, an extended-release oxycodone drug, Embeda, an extended-release morphine

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics